3VM1001

3VM1001 is a topical cream developed by CDA Research Group for the treatment of chronic pain associated with osteoarthritis of the knee and post-herpetic neuralgia. The active pharmaceutical ingredient in this formulation is copper, delivered in a low concentration within a cream vehicle. The drug is intended to provide pain relief through topical application and aims to address an unmet need for effective local therapies with fewer systemic side effects compared to current first- and second-line treatments such as tricyclic antidepressants, anticonvulsants (gabapentin, pregabalin), lidocaine patches, opioids, or capsaicin[1][2][4][5][7]. The precise mechanism of action remains undefined; however, it is classified as an analgesic and antirheumatic agent[2][3]. Clinical trials have evaluated its safety and efficacy in both osteoarthritis-related knee pain (Phase I/II) and post-herpetic neuralgia (early Phase I)[2][4][7].

Other names

3VM1001 cream